- Lobbying
- Lobbying by Novartis Corporation
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jim McCrery | Former Member of Congress, Louisiana 4th district; Ranking member, House Ways and Means Committee; Committee Member, Joint Committee on Taxation. |
David Olander | Legislative Assistant, Rep. Wally Herger; Tax & Policy Counsel, Rep. Thomas Reynolds; Tax Counsel & Chief Tax Counsel, House Committee on Ways and Means. |
Ann Jablon | Chief of Staff, Rep. Richard Neal. |
Aaron Cohen | Chief of Staff & Legislative Assistant, Sen. John Ensign; Legislative Aide, Sen. Richard Bryan; Legislative Corresp., Sen. Richard Bryan. |
Drew Goesl | Chief of Staff, Rep. Mike Ross; Communications Director, Sen. Blanche Lincoln. Chief of Staff, Rep. Mike Ross; Communications Director, Sen. Blanche Lincoln. |
Bob Brooks | Chief of Staff, Rep. Jim McCrery & Rep. Jay Dickey. |
John D. Rafaelli | n/a |
Shannon Finnley | n/a |
Denise Henry Morrisey | n/a |
Shannon Finley | n/a |
John D. Raffaelli | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medicare
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medicare
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medicare
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medicare
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q4 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medicare
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Q3 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medicare
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Lobbying activities will include representation of Novartis in Congress and the Executive Branch on issues related to tax reform or tax legislation, generally, as well as issues affecting pharmaceuticals, particularly as relate to efforts to repeal and replace the Affordable Care Act, and Medicare and Medicaid..
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Medicare
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Lobbying activities will include representation of Novartis in Congress and the Executive Branch on issues related to tax reform or tax legislation, generally, as well as issues affecting pharmaceuticals, particularly as relate to efforts to repeal and replace the Affordable Care Act, and Medicare and Medicaid..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate